TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31045947

Group type: EXPERIMENTAL
Intervention: Antiresorptive drugs (i.e. bisphosphonates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone anabolic drugs (i.e. teriparatide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study: 28541802

Group type: EXPERIMENTAL
Intervention: Integrated treatment for co-occurring PTSD and substance use disorder
Number of subjects: 15
Study: 24945268

Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 255

Group type: COMPARATOR
Intervention: Moisturizing cream
Number of subjects: 255
Study: 23474995

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training for 20 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 21457842

Group type: EXPERIMENTAL
Intervention: 2.5° buccal root torque
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15° buccal root torque
Number of subjects: 15
Study: 19021095

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 0
Study: 17213476

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg for 21 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15502736

Group type: EXPERIMENTAL
Intervention: Patients with stroke
Number of subjects: 80
Study: 11776423

Group type: EXPERIMENTAL
Intervention: Memory Structuring Intervention (MSI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Supportive-listening control sessions
Number of subjects: 17
Study: 9187784

Group type: EXPERIMENTAL
Intervention: Clonidine 9 micrograms.kg‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms.kg‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine 6 micrograms.kg‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (0 micrograms.kg‐1)
Number of subjects: 6
Study: 7943597

Group type: EXPERIMENTAL
Intervention: Postoperative hepatic perfusion chemotherapy via hepatic artery and portal vein with 5-fluorouracil (125 mg/d) for 28 to 35 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Historical control groups
Number of subjects: 20
Study: 2835743

Group type: EXPERIMENTAL
Intervention: Combined measles, mumps, rubella, and varicella vaccine
Number of subjects: 0
Study: 31116739

Group type: EXPERIMENTAL
Intervention: Collaborative learning with metacognitive prompts
Number of subjects: 171

Group type: COMPARATOR
Intervention: Collaborative learning without metacognitive prompts
Number of subjects: 171

Group type: COMPARATOR
Intervention: Individual learning with metacognitive prompts
Number of subjects: 171

Group type: COMPARATOR
Intervention: Individual learning without metacognitive prompts
Number of subjects: 171
Study: 27778643

Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (CR) for 12 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ad libitum (control) diet for 12 months
Number of subjects: 51
Study: 26195058

Group type: EXPERIMENTAL
Intervention: GA40 (40 mg/mL three-times weekly)
Number of subjects: 209

Group type: COMPARATOR
Intervention: GA20 (20 mg/mL daily)
Number of subjects: 209
Study: 23877462

Group type: EXPERIMENTAL
Intervention: Vertebral augmentation procedures with advanced imaging (MRI, CT, or bone scan)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Vertebral augmentation procedures with Workers compensation
Number of subjects: 409
Study: 21904088

Group type: EXPERIMENTAL
Intervention: MAS extended release (MAS XR)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MAS immediate release (MAS IR)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MAS IR and MAS XR
Number of subjects: 62
Study: 19121433

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 5745

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 5745
Study: 16940098

Group type: EXPERIMENTAL
Intervention: Fusidic acid
Number of subjects: 114

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 114
Study: 15078379

Group type: EXPERIMENTAL
Intervention: 0.45 mg.kg(‐1) rocuronium bromide
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.6 mg.kg(‐1) rocuronium bromide
Number of subjects: 61
Study: 10903790

Group type: EXPERIMENTAL
Intervention: O + M + L
Number of subjects: 135

Group type: COMPARATOR
Intervention: O + M
Number of subjects: 135
Study: 9285652

Group type: EXPERIMENTAL
Intervention: 480 mg/day diltiazem (morning dosing)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 480 mg/day diltiazem (evening dosing)
Number of subjects: 68
Study: 8324395

Group type: EXPERIMENTAL
Intervention: Seldane-D (terfenadine 60 mg + pseudo-ephedrine 120 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pseudo-ephedrine (120 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3574053

Group type: EXPERIMENTAL
Intervention: Bicycling for 1 hour at 60% VO2max
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Running for 1 hour at 60% VO2max
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control sessions (5 subjects)
Number of subjects: 10
Study: 31693129

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Number of subjects: 6097

Group type: EXPERIMENTAL
Intervention: Oral clodronate
Number of subjects: 6097

Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 6097
Study: 31330502

Group type: EXPERIMENTAL
Intervention: Suspension Training (ST)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (RT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 57
Study: 27457511

Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 or 1.5 mg three times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 mg three times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25980735

Group type: EXPERIMENTAL
Intervention: 25-minute interval between tumescent anesthetic solution infiltration and start of surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: 15-minute interval between tumescent anesthetic solution infiltration and start of surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: 10-minute interval between tumescent anesthetic solution infiltration and start of surgery
Number of subjects: 75
Study: 23205588

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 69
Study: 21813223

Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentrations of 0.4, 0.8, 1.2, 1.6, and 2.0 μg/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentrations of 1.6 and 2.0 μg/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentration of 2.0 μg/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentration of 1.2 μg/mL or less
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol group
Number of subjects: 20
Study: 19231302

Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam and placebo throat spray (midazolam group)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Placebo sedation and pharyngeal anaesthesia with lidocaine (lidocaine group)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Placebo sedation and placebo throat spray (placebo group)
Number of subjects: 213

Group type: COMPARATOR
Intervention: No intravenous cannula nor throat spray (control group)
Number of subjects: 213
Study: 16698410

Group type: EXPERIMENTAL
Intervention: Aminophylline (250 mg, and an additional 250 mg if necessary)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 971

Group type: COMPARATOR
Intervention: Aminophylline and Placebo
Number of subjects: 971
Study: 15321793

Group type: EXPERIMENTAL
Intervention: 1000 kcal/d diet with 4 servings/d of liquid meal replacement (MR)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 1200-1500 kcal/d balanced deficit diet (BDD)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nondieting (ND) approach
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MR and BDD
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MR
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study: 11798062

Group type: EXPERIMENTAL
Intervention: Randomly allocated interventions in controlled clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific endpoint selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific endpoint event rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific therapy efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific nonuniform type I error levels
Number of subjects: 0
Study: 9669257

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no L-arginine)
Number of subjects: 36
Study: 8077575

Group type: EXPERIMENTAL
Intervention: Soy-based formula with 2.91 g protein/100 kcal (IS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Soy-based formula with 2.45 g protein/100 kcal (EF)
Number of subjects: 64
Study: 2758453

Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 364781

Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation (neutral red 1% solution + 15-min exposure to 40 watt light of 440-550 nm)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carbolization
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idoxuridine (IDU) ointment
Number of subjects: 21
Study: 29373661

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 168
Study: 28851784

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 µg daily from early pregnancy until 6 months postpartum)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (daily from early pregnancy until 6 months postpartum)
Number of subjects: 800
Study: 26592377

Group type: EXPERIMENTAL
Intervention: Single-unit PRBC transfusion
Number of subjects: 230

Group type: COMPARATOR
Intervention: Double-unit PRBC transfusion
Number of subjects: 230
Study: 24286136

Group type: EXPERIMENTAL
Intervention: Brodalumab (50 mg, 140 mg, or 210 mg subcutaneously every two weeks for 6 doses; or 420 mg or 700 mg intravenously every 4 weeks for two doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21062790

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol‐remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced anaesthesia (BAL) with fentanyl‐nitrous oxide‐sevoflurane
Number of subjects: 60
Study: 18467185

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1500 microg every 4 weeks with oral ribavirin 800 mg/day for 24 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Albinterferon alfa-2b 1500 microg every 2 weeks with oral ribavirin 800 mg/day for 24 weeks
Number of subjects: 43
Study: 17096501

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injection
Number of subjects: 0
Study: 14648885

Group type: EXPERIMENTAL
Intervention: High-field (3.0 T) magnetic resonance (MR) system
Number of subjects: 16
Study: 10853700

Group type: EXPERIMENTAL
Intervention: Electrostimulation training for 7 weeks (5 series of 6 6-s isometric actions at 60 to 70% of maximal isometric voluntary action)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Electrostimulation training for 7 weeks
Number of subjects: 9
Study: 9357405

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 8375243

Group type: EXPERIMENTAL
Intervention: Oral glucose (10 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral glucose (20 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous glucagon (1.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral Ala (40 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3514202

Group type: EXPERIMENTAL
Intervention: SMA Low Birth Weight
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Prematalac
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Preaptamil
Number of subjects: 85

Group type: COMPARATOR
Intervention: Expressed Breast Milk (EBM)
Number of subjects: 85
Study: 31394948

Group type: EXPERIMENTAL
Intervention: RAM cannula
Number of subjects: 126
Study: 29480440

Group type: EXPERIMENTAL
Intervention: Weekly short-term lotteries for 13 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term lotteries in combination with an additional long-term lottery after 26 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm without lottery-deadlines
Number of subjects: 0

Group type: COMPARATOR
Intervention: All arms (including control)
Number of subjects: 0
Study: 27019158

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg single dose after high-fat breakfast
Number of subjects: 15

Group type: COMPARATOR
Intervention: Faldaprevir 240 mg single dose in fasting state
Number of subjects: 15

Group type: COMPARATOR
Intervention: Faldaprevir 240 mg single dose with omeprazole 40 mg q.d. for 5 days
Number of subjects: 15
Study: 24885833

Group type: EXPERIMENTAL
Intervention: Amino acid‐based formula (AAF) for 80 days starting at SD5 (CD-C)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Amino acid‐based formula (AAF) for 80 days starting at SD5 (CD-I)
Number of subjects: 46
Study: 24204067

Group type: EXPERIMENTAL
Intervention: Partnerships for Health QI program
Number of subjects: 998
Study: 21921426

Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg preoperative dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 60
Study: 18640826

Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD in the morning
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD in the evening
Number of subjects: 1537

Group type: COMPARATOR
Intervention: MF‐DPI 400 microg QD in the morning and evening
Number of subjects: 1537
Study: 16612448

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice a day for one week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12531630

Group type: EXPERIMENTAL
Intervention: 1mg CS6 in PLG microspheres with buffer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5mg CS6 in PLG microspheres with buffer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1mg CS6 as free protein in saline
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5mg CS6 as free protein in saline
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1mg CS6 in PLG microspheres with rice-based buffer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5mg CS6 in PLG microspheres with rice-based buffer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1mg CS6 as free protein in rice-based buffer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5mg CS6 as free protein in rice-based buffer
Number of subjects: 5
Study: 10951629

Group type: EXPERIMENTAL
Intervention: Domestic glutathione (GSH) - continuous infusion of 600g daily for 30 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: TAD - same dosage, course and route as GSH
Number of subjects: 110
Study: 8831579

Group type: EXPERIMENTAL
Intervention: Octreoscan scintigraphy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional imaging techniques
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of conventional techniques and Octreoscan scintigraphy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Endoscopic ultrasonography
Number of subjects: 21
Study: 1426513

Group type: EXPERIMENTAL
Intervention: Iodostearic acid pessaries in polyethylene glycol (PEG) base
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEG base pessaries
Number of subjects: 0
Study: 2883063

Group type: EXPERIMENTAL
Intervention: Coronary intensive care units (CCU) with higher hospitalization/year and more sophisticated instrumental equipment
Number of subjects: 20020

Group type: EXPERIMENTAL
Intervention: Patients hospitalized within the first few hours from symptom onset
Number of subjects: 20020

Group type: COMPARATOR
Intervention: Patients hospitalized after 12 hours
Number of subjects: 20020
Study: 31745744

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Myocardial perfusion scintigraphy (MPS) or cardiovascular magnetic resonance (CMR)
Number of subjects: 176
Study: 29045582

Group type: EXPERIMENTAL
Intervention: Multifactorial fall injury prevention strategy (comanagement model with nurse Falls Care Manager)
Number of subjects: 5451

Group type: COMPARATOR
Intervention: Enhanced usual care (evidence-based information on falls prevention)
Number of subjects: 5451
Study: 25834276

Group type: EXPERIMENTAL
Intervention: Alexander Technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Local heat application
Number of subjects: 72

Group type: COMPARATOR
Intervention: Guided imagery
Number of subjects: 72
Study: 24033830

Group type: EXPERIMENTAL
Intervention: Programmed shock at 20 ms before peak (Group I)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Programmed shock at peak (Group II)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Programmed shock at 20 ms after peak (Group III)
Number of subjects: 200
Study: 22170706

Group type: EXPERIMENTAL
Intervention: Exercise-induced β-endorphin levels above 25 pg/ml (n = 7)
Number of subjects: 16
Study: 20158290

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25 mg/70 kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (0.40, 0.80 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study: 18514870

Group type: EXPERIMENTAL
Intervention: 3 braided cables
Number of subjects: 9

Group type: COMPARATOR
Intervention: 2 braided cables
Number of subjects: 9
Study: 16872896

Group type: EXPERIMENTAL
Intervention: 0.2% Lavasept solution (n=28)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ringer solution (n=22)
Number of subjects: 50
Study: 15641497

Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum (65% xylitol), 6 pieces daily for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sorbitol-containing chewing gum (control), 6 pieces daily for 14 days
Number of subjects: 10
Study: 10604694

Group type: EXPERIMENTAL
Intervention: Bardex I.C. hydrogel/silver-coated Foley catheter
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard latex Foley catheter
Number of subjects: 5
Study: 7780067

Group type: EXPERIMENTAL
Intervention: Epidural meperidine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous PCA meperidine infusion
Number of subjects: 0
Study: 2277298

Group type: EXPERIMENTAL
Intervention: Azathioprine and steroids with 28 days of intravenous antithymocyte globulin
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Cyclosporine and low-dose steroids
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Cyclosporine and azathioprine
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Triple therapy (not specified)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 275
Study: 416647

Group type: EXPERIMENTAL
Intervention: Maximum external megavoltage irradiation, 5,000 rads
Number of subjects: 302

Group type: COMPARATOR
Intervention: Reduced dose irradiation, 3,000 rads followed by chemotherapy with Thio‐tepa
Number of subjects: 302
Study: 31727073

Group type: EXPERIMENTAL
Intervention: Quality improvement approach for recruitment and retention
Number of subjects: 722
Study: 28691417

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied during PCI at a dose of 9 J/cm2
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (PCI only)
Number of subjects: 52
Study: 26435259

Group type: EXPERIMENTAL
Intervention: Active gaming with food and drink offered ad libitum
Number of subjects: 21

Group type: COMPARATOR
Intervention: Seated gaming with food and drink offered ad libitum
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Active gaming (no food or drink)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Seated gaming (no food or drink)
Number of subjects: 21
Study: 23321244

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)(2)) paste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control (deionized water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (bipaste)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste (tripaste)
Number of subjects: 0
Study: 22129567

Group type: EXPERIMENTAL
Intervention: Test formulation (ferrous succinate, 200 mg [100 mg × 2])
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation (Sulifei, 200 mg [100 mg × 2])
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study: 19620517

Group type: EXPERIMENTAL
Intervention: Low sodium diet (50 mmol/24 hours x 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High sodium diet (250 mmol/24 hours x 7 days)
Number of subjects: 12
Study: 16387501

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 109

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 109
Study: 15663236

Group type: EXPERIMENTAL
Intervention: Ropivacaine mesylate (15 ml of 8.94 mg/ml for anesthesia and 2.374 mg/ml for analgesia)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ropivacaine hydrochloride (15 ml of 7.5 mg/ml for anesthesia and 2 mg/ml for analgesia)
Number of subjects: 44
Study: 11243638

Group type: EXPERIMENTAL
Intervention: Neoprene gloves
Number of subjects: 8

Group type: COMPARATOR
Intervention: Poorest glove
Number of subjects: 8